These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 17654723)
1. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Liu W; Ewing CM; Chang BL; Li T; Sun J; Turner AR; Dimitrov L; Zhu Y; Sun J; Kim JW; Zheng SL; Isaacs WB; Xu J Genes Chromosomes Cancer; 2007 Nov; 46(11):972-80. PubMed ID: 17654723 [TBL] [Abstract][Full Text] [Related]
2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
3. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688 [TBL] [Abstract][Full Text] [Related]
5. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440 [TBL] [Abstract][Full Text] [Related]
6. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460 [TBL] [Abstract][Full Text] [Related]
8. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Dong J; Xiao L; Sheng L; Xu J; Sun ZQ Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454 [TBL] [Abstract][Full Text] [Related]
10. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mehra R; Tomlins SA; Shen R; Nadeem O; Wang L; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM; Shah RB Mod Pathol; 2007 May; 20(5):538-44. PubMed ID: 17334343 [TBL] [Abstract][Full Text] [Related]
12. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739 [TBL] [Abstract][Full Text] [Related]
13. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. Smit FP; Salagierski M; Jannink S; Schalken JA BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236 [TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139 [TBL] [Abstract][Full Text] [Related]
15. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Attard G; Clark J; Ambroisine L; Fisher G; Kovacs G; Flohr P; Berney D; Foster CS; Fletcher A; Gerald WL; Moller H; Reuter V; De Bono JS; Scardino P; Cuzick J; Cooper CS; Oncogene; 2008 Jan; 27(3):253-63. PubMed ID: 17637754 [TBL] [Abstract][Full Text] [Related]
16. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers. Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216 [TBL] [Abstract][Full Text] [Related]
18. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
19. Retention of Interstitial Genes between Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096 [No Abstract] [Full Text] [Related]
20. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Liu W; Chang B; Sauvageot J; Dimitrov L; Gielzak M; Li T; Yan G; Sun J; Sun J; Adams TS; Turner AR; Kim JW; Meyers DA; Zheng SL; Isaacs WB; Xu J Genes Chromosomes Cancer; 2006 Nov; 45(11):1018-32. PubMed ID: 16897747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]